Guangxi Wuzhou Zhongheng Group (600252) Fair Value & Analysis
Healthcare · CN · Market cap 6.9B CNY
Fair value as of: Jul 11, 2026
From 3 valuation models · updated today
Fair value updated Jul 11, 2026 — revised from ¥7.59 to ¥0.3800 (−95.0%) since Jun 24, 2026. Share price −9.6% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥1.73 – ¥2.93 · fair‑value band ¥0.1700 – ¥0.6500 · the ¥1.92 price screens above the ¥0.3800 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Guangxi Wuzhou Zhongheng Group (600252) currently trades at ¥1.92, while our model-based Fair Value estimate is ¥0.3800 — implying the stock looks roughly 80.2% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Guangxi Wuzhou Zhongheng Group generated revenue of 1.6B CNY at a net margin of -25.8%. Revenue declined 52.1% year over year. It earns a return on equity of -7.7%. The balance sheet holds a net cash position of 2.3B CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥0.1700 (bear case) to ¥0.6500 (bull case); at ¥1.92, the current price sits above that range. The share trades about 41% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -80%, 600252 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for cardiovascular and cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, and other healthcare applications. It also provides clindamycin hydrochloride injection, esomeprazole sodium injection, esomeprazole magnesium enteric-coated capsules, cefoperazone dry suspension, naloxone hydrochloride injection, and fludarabine phosphate injection. Further, the company is involved in production of oral care, clothing care, and home care products, including toothpaste; health food business; pharmaceutical distribution; project …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Guangxi Wuzhou Zhongheng Group reported revenue of ¥1.7B in FY2025 versus ¥3.2B in FY2021, a compound −13.8%/yr. Reported net income was −¥357M in FY2025.
Is 600252 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Guangxi Wuzhou Zhongheng Group (600252) undervalued?
What is the fair value of 600252?
What is the quality score of 600252?
What is the revenue of Guangxi Wuzhou Zhongheng Group (600252)?
What is the net profit margin of 600252?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.